Welcome to our dedicated page for EUDA Health Holdings SEC filings (Ticker: EUDAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on EUDA Health Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into EUDA Health Holdings's regulatory disclosures and financial reporting.
EUDA Health Holdings Ltd amended its annual report describing continued operating losses, a May 8, 2024 acquisition of CK Health Plus Sdn Bhd and significant non-cash impairment charges. The Company reported 37,153,049 ordinary shares outstanding as of December 31, 2024 and recorded a $14,755,560 impairment of intangible assets in 2024.
Management disclosed substantial doubt about the Company’s ability to continue as a going concern within one year, noting recurring losses since 2020, cash of approximately $0.2 million and a need to raise additional financing. The CK Health acquisition was settled with 8,571,428 newly issued shares valued at $15.0 million (at $1.75 per share), plus a contingent 1,000,000-share earnout tied to 2024–2025 net income milestones.
EUDA Health Holdings Ltd. (Nasdaq: EUDA) has filed a Form 424(b)(5) prospectus supplement to register up to 5,000,000 ordinary shares underlying a US$10 million one-year convertible note to be sold to Indigo Capital LP in a registered-direct transaction. Notes are issued at a 10 % original-issue discount (net cash ≈ US$9 million; estimated net proceeds after expenses ≈ US$8.98 million) and convert at 85 % of the share’s Nasdaq close on the conversion date, capped at 4.99 % beneficial ownership. A 5-day closing bid below US$2.00 constitutes an “Early Default,” accelerating repayment or conversion; no interest accrues. No public market will exist for the notes.
The financing adds to an already highly dilutive capital structure: 37.16 million shares outstanding, 8.9 million warrants and other convertibles. FY-2024 results showed a US$15.4 million net loss, US$3.4 million working-capital deficit and only US$0.2 million cash. The auditor issued a going-concern warning and management cited material-control weaknesses. Proceeds are earmarked for working capital, M&A and general corporate purposes.
EUDA is pivoting from low-demand medical clinics to wellness services after acquiring CK Health (2.2 % of 2024 revenue) and partnering for stem-cell packages. Two large shareholders control ~53 % of equity, and resale registration rights could pressure the stock. Investors face execution, dilution, and delisting risks offset by near-term liquidity from the note.
FAQ
What is the current stock price of EUDA Health Holdings (EUDAW)?
